Welcome to IgMin Research – an Open Access journal uniting Biology, Medicine, and Engineering. We’re dedicated to advancing global knowledge and fostering collaboration across scientific fields.
At IgMin Research, we bridge the frontiers of Biology, Medicine, and Engineering to foster interdisciplinary innovation. Our expanded scope now embraces a wide spectrum of scientific disciplines, empowering global researchers to explore, contribute, and collaborate through open access.
Welcome to IgMin, a leading platform dedicated to enhancing knowledge dissemination and professional growth across multiple fields of science, technology, and the humanities. We believe in the power of open access, collaboration, and innovation. Our goal is to provide individuals and organizations with the tools they need to succeed in the global knowledge economy.
IgMin Publications Inc., Suite 102, West Hartford, CT - 06110, USA
We are dedicated to advancing research by promoting dialogue between diverse scientific communities.
Biography
Dr. Cristina Filosa is a researcher specializing in the stability of pharmaceutical compounds, particularly within medical devices. She is affiliated with Biofordrug S.r.l., a spin-off of the University of Bari Aldo Moro, located in Triggiano, Bari, Italy. Her work focuses on the analytical assessment of chemotherapy agents, antibiotics, and radiotracers using advanced techniques such as LC-QqQ-MS (Liquid Chromatography-Quadrupole-Quadrupole-Mass Spectrometry).
Dr. Filosa holds a Master's degree in Chemical Sciences from the University of Bari Aldo Moro. Her academic and professional endeavors are centered on ensuring the stability and efficacy of pharmaceutical products, contributing significantly to the field of pharmaceutical sciences.
In addition to her research at Biofordrug, Dr. Filosa has co-authored several publications in scientific journals. Notably, she contributed to a study titled "LC-MS and HPLC-UV for Detecting Uremic Toxins: Two Validated Methods with Simultaneous Sensitivity and Specificity Evaluation," published in April 2024. This work underscores her expertise in analytical chemistry and its application to medical diagnostics.
Dr. Filosa's contributions are instrumental in advancing the understanding and development of stable pharmaceutical formulations, ensuring their safety and effectiveness in medical applications.
Research Interest
Dr. Cristina Filosa's research interests primarily focus on pharmaceutical sciences, with a particular emphasis on the stability and efficacy of pharmaceutical compounds. Her work explores the development and validation of analytical methods, such as Liquid Chromatography-Quadrupole-Quadrupole-Mass Spectrometry (LC-QqQ-MS), for assessing the quality and stability of drugs, especially chemotherapy agents, antibiotics, and radiotracers. Dr. Filosa is dedicated to ensuring the safety and therapeutic effectiveness of pharmaceutical products by applying advanced analytical techniques to assess their chemical stability under various conditions. She is also interested in the optimization of medical device formulations and the development of reliable methodologies for detecting uremic toxins in clinical diagnostics. In her capacity as a researcher at Biofordrug, a spin-off from the University of Bari Aldo Moro, Dr. Filosa contributes significantly to advancing the field of pharmaceutical analysis, ensuring that medical treatments are both safe and effective for patient use.
Open Access Policy refers to a set of principles and guidelines aimed at providing unrestricted access to scholarly research and literature. It promotes the free availability and unrestricted use of research outputs, enabling researchers, students, and the general public to access, read, download, and distribute scholarly articles without financial or legal barriers. In this response, I will provide you with an overview of the history and latest resolutions related to Open Access Policy.
Uremic toxins (UTs) are compounds derived from the metabolism of dietary molecules such as tryptophan (Indossyl Sulphate, IS) and phenil-alanine (P-Cresyl Sulphate, PCS), that are normally eliminated by the kidneys of healthy patients. The accumulation of such toxins is an indicator of kidney disease at different degrees of severity, and the toxins can be found as free or protein bound in human biological samples. The toxicity of such compounds causes the loss of several biological functions, and the subjects suffering from such complications w...ill need, more often than not, hemodialysis to properly excrete these toxins. Despite this not being a resolutive, but rather a symptom managing clinical approach, this is the most common course of treatment. Two analytical methods are proposed to quantify both the protein-bound and free forms of IS and PCS (HPLC-UV for the former; LC-MS/MS with ESI negative ionization for the latter), with lower variability and higher robustness than what is currently proposed, allowing for a precise simultaneous determination of the aforementioned UTs.
0000-0002-6769-7610 
